Active Ingredient History
Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Basal Cell (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Merkel Cell (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Phase 1)
Carcinoma, Squamous Cell (Phase 3)
Diffuse Intrinsic Pontine Glioma (Phase 1/Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 1)
Hepatitis B virus (Phase 1/Phase 2)
HIV Infections (Phase 1/Phase 2)
Hodgkin Disease (Phase 2)
Hypopharyngeal Neoplasms (Phase 2)
Laryngeal Neoplasms (Phase 2)
Lymphoma (Phase 1/Phase 2)
Lymphoma, T-Cell (Phase 2)
Melanoma (Phase 2)
Mouth Neoplasms (Phase 2)
Multiple Myeloma (Phase 1/Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 2)
Oropharyngeal Neoplasms (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 1/Phase 2)
Sarcoma (Phase 2)
Skin Neoplasms (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
